Progenics Pharmaceuticals Articles
AstraZeneca's Brilinta gains Class I in ACCF/AHA Guidelines; enters deal with Progenics
18 December 2012
CytoDyn to acquire Progenics' PRO 140
31 July 2012
Progenics Pharma grants rights to Salix for Relistor, in upfront $60 million and potential $290 million more deal
8 February 2011
Showing 1-4 of 4 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
